EUVIMEDEUVIMED entdecken
Kohortenstudie

Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study With Nineteen‐Year Follow‐up

Mercedes E Quiñones, Joyce K Joseph, Sharon Dowell, Hans J Moore, Pamela E Karasik, Gregg C Fonarow, Ross D Fletcher, Yan Cheng, Qing Zeng-Treitler, Cherinne Arundel, Angelike P Liappis, Helen M Sheriff und 6 weitere

Arthritis Care & Research · 2023

DOI: 10.1002/acr.25005 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Arthritis Care & Research, 2023. Verfasst von Mercedes E Quiñones und 17 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Affairs Medical Center, and Howard University, Washington, DC. Hauptthemen laut MEDLINE: Veterans, Arthritis, Rheumatoid, Antirheumatic Agents, Long QT Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Recent evidence suggests that hydroxychloroquine use is not associated with higher 1‐year risk of long QT syndrome (LQTS) in patients with rheumatoid arthritis (RA). Less is known about its long‐term risk, the examination of which was the objective of this study.

Methods

We conducted a propensity score–matched active‐comparator safety study of hydroxychloroquine in 8,852 veterans (mean age 64 ± 12 years, 14% women, 28% Black) with newly diagnosed RA. A total of 4,426 patients started on hydroxychloroquine and 4,426 started on another nonbiologic disease‐modifying antirheumatic drug (DMARD) and were balanced on 87 baseline characteristics. The primary outcome was LQTS during 19‐year follow‐up through December 31, 2019.

Results

Incident LQTS occurred in 4 (0.09%) and 5 (0.11%) patients in the hydroxychloroquine and other DMARD groups, respectively, during the first 2 years. Respective 5‐year incidences were 17 (0.38%) and 6 (0.14%), representing 11 additional LQTS events in the hydroxychloroquine group (number needed to harm 403; [95% confidence interval (95% CI)], 217–1,740) and a 181% greater relative risk (95% CI 11%–613%; P = 0.030). Although overall 10‐year risk remained significant (hazard ratio 2.17; 95% CI 1.13–4.18), only 5 extra LQTS occurred in hydroxychloroquine group over the next 5 years (years 6–10) and 1 over the next 9 years (years 11–19). There was no association with arrhythmia‐related hospitalization or all‐cause mortality.

Conclusions

Hydroxychloroquine use had no association with LQTS during the first 2 years after initiation of therapy. There was a higher risk thereafter that became significant after 5 years of therapy. However, the 5‐year absolute risk was very low, and the absolute risk difference was even lower. Both risks attenuated during longer follow‐up. These findings provide evidence for long‐term safety of hydroxychloroquine in patients with RA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VeteransArthritis, RheumatoidAntirheumatic AgentsLong QT SyndromeHumansFemaleMiddle AgedAgedMaleHydroxychloroquineCohort StudiesFollow-Up StudiesRetrospective StudiesMethotrexate

Substanzen

HydroxychloroquineAntirheumatic AgentsMethotrexate

Autor:innen und Institutionen

  • Veterans Affairs Medical Center, and Howard University, Washington, DC.
  • Veterans Affairs Medical Center, Washington, DC.
  • Veterans Affairs Medical Center, Georgetown University, George Washington University, Uniformed Services University, and US Department of Veterans Affairs, Washington, DC.
  • Veterans Affairs Medical Center, Georgetown University, George Washington University, and Uniformed Services University, Washington, DC.
  • University of California, Los Angeles, CA.
  • Veterans Affairs Medical Center and George Washington University, Washington, DC.

ORCID-Profile: Ali Ahmed

Förderung

  • U.S. Department of Veterans Affairs

Zitieren

APA

Quiñones, M. E., Joseph, J. K., Dowell, S., Moore, H. J., Karasik, P. E., Fonarow, G. C., Fletcher, R. D., Cheng, Y., Zeng-Treitler, Q., Arundel, C., Liappis, A. P., Sheriff, H. M., Zhang, S., Taub, D. D., Heimall, M. S., Faselis, C., Kerr, G. S., & Ahmed, A. (2023). Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study With Nineteen‐Year Follow‐up. Arthritis Care & Research. https://doi.org/10.1002/acr.25005

Vancouver

Quiñones ME, Joseph JK, Dowell S, Moore HJ, Karasik PE, Fonarow GC, et al. Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study With Nineteen‐Year Follow‐up. Arthritis Care & Research. 2023. doi:10.1002/acr.25005

BibTeX
@article{Quiones2023,
  author = {Quiñones, Mercedes E and Joseph, Joyce K and Dowell, Sharon and Moore, Hans J and Karasik, Pamela E and Fonarow, Gregg C and Fletcher, Ross D and Cheng, Yan and Zeng-Treitler, Qing and Arundel, Cherinne and Liappis, Angelike P and Sheriff, Helen M and Zhang, Sijian and Taub, Daniel D and Heimall, Michael S and Faselis, Charles and Kerr, Gail S and Ahmed, Ali},
  title = {Hydroxychloroquine and Risk of Long QT Syndrome in Rheumatoid Arthritis: A Veterans Cohort Study With Nineteen‐Year Follow‐up},
  journal = {Arthritis Care & Research},
  year = {2023},
  doi = {10.1002/acr.25005}
}
Kostenlos starten →